Please assess the completion status of the following clinical trial:

Trial Title: Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a moderate renal insufficiency defined by a creatinine clearance between 30 to 50 ml/min (Cockcroft and Gault formulae) or a severe renal insufficiency (between 15 to 29 ml/min)~* Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis), planned to be treated for at least 3 months~* Patients \>18 years~* Life expectancy more than 3 months~* Social security affiliation~* Signed informed consent~Exclusion Criteria:~* Indication for anticoagulants other than VTE~* Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg~* Anticoagulation for more than 72 hours prior to randomization~* Chronic liver disease or chronic hepatitis~* Patient at high risk of bleeding~* Creatinine clearance \<15 ml/min or end stage renal disease or indication for extra-renal dialysis~* Need for concomitant anti-platelet therapy other than aspirin 75-325 mg per day. However concomitant treatment with aspirin is discouraged in this population at bleeding risk.~* Concomitant use of a strong inhibitor of cytochrome P-450 3A4 (CYP3A4) (e.g., a protease inhibitor for human immunodeficiency virus infection or azole-antimycotics agents ketoconazole, itraconazole, voriconazole, posaconazole) or a CYP3A4 inducer (e.g., rifampin, carbamazepine, or phenytoin),~* Active pregnancy or expected pregnancy or no effective contraception~* Any contraindication listed in the local labeling of UFH, LMWH or VKA or oral anticoagulant.~* Cancer-associated VTE requiring long-term treatment with LMWH~* Life expectancy of less than 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DOA : Direct Oral Anticoagulants (Type: EXPERIMENTAL): The experimental group receiving DOA regimens: patients will be secondarily randomly assigned within DOAs group between:~* Apixaban (Eliquis® tablet) 10 mg bid for 7 days then 2.5 mg bid for 3 months~* Rivaroxaban (Xarelto® tablet) 15 mg bid for 21 days then 15 mg od for 3 months.
- SOC : Standard Of Care (Type: ACTIVE_COMPARATOR): The control group receiving the standard of care (SOC), i.e. heparins/VKA regimen. Patients will receive the current recommended therapy: subcutaneous or intravenous UFH/VKA in case of severe renal insufficiency and subcutaneous LMWH/VKA in case of moderate renal insufficiency for at least 5 days. VKA will begin concomitantly and continue for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).